TMCnet News

Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer
[April 22, 2019]

Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer


BERKELEY, Calif., April 22, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways, today announced the appointment of Dimitry S.A. Nuyten, M.D., Ph.D., as Chief Medical Officer.

Dimitry S.A. Nuyten, M.D., Ph.D.
Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer


“Dimitry’s expertise as a radiation oncologist specializing in cancer biology and his experience leading immuno-oncology clinical strategy and development will be instrumental to Aduro,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We are extremely pleased to welcome Dimitry as we prepare to broaden our development plans for STING agonist ADU-S100 and initiate our first in human study of anti-APRIL antibody BION-1301 in IgA nephropathy.”

Dr. Nuyten will join Aduro from Pfizer where he most recently served as Vice President and Immuno-Oncology Clinical Development Leader and oversaw the clinical strategy for BAVENCIO® (avelumab), a human anti-programmed death ligand-1 (PD-L1) antibody, utomilumab, a human monoclonal antibody (mAb) agonist that selectively binds to 4-1BB and additional programs that included pivotal and exploratory trials with immuno-oncology combinations. Prior to Pfizer, he served as Group Medical Director and Exploratory Development Team Leader at Bristol-Myers Squibb, where he was responsible for the development of several early phase compounds in oncology. Dr. Nuyten holds an M.D. from the University of Groningen and a Ph.D. from the University of Amsterdam Medical School in The Netherlands and completed his training in radiation oncology at the Netherlands Cancer Institute (NKI). He has authored numerous peer-reviewed publications and is co-inventor on multiple patents. 

“I am excited to join Aduro and continue building the company’s leadership position in STING and APRIL biology,” sid Dr. Nuyten. “I look forward to collaborating with Aduro’s clinical team and our external partners to generate additional data while making a meaningful impact for patients.”



About Aduro
Aduro Biotech, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Aduro’s product candidates in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways are being investigated in cancer, autoimmune and inflammatory diseases. ADU-S100 (MIW815), which potentially activates the intracellular STING receptor for a potent tumor-specific immune response, is being evaluated in patients with cutaneously accessible metastatic solid tumors or lymphomas. BION-1301, a fully blocking monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors, is being evaluated in multiple myeloma and as a potential treatment for IgA nephropathy. Aduro is collaborating with a number of leading global pharmaceutical companies to help expand and drive its product pipeline. For more information, please visit www.aduro.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the value and contributions that Dr. Nuyten will provide as our Chief Medical Officer, the potential for our STING and APRIL programs, the broadening of our development plans for our STING and APRIL programs, our ability to build our leadership position in STING and APRIL biology, our ability to generate clinical data and our ability to make a meaningful impact for patients. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions.  Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, early or preliminary clinical trial results may not be predictive of future results, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technologies to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates.  We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our annual report on Form 10-K for the year ended December 31, 2018, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


Investor Relations Contact:Media Contact:
Noopur LiffickAljanae Reynolds
510-809-2465510-809-2452
[email protected][email protected]

A photo accompanying this announcement is available at //www.globenewswire.com/NewsRoom/AttachmentNg/f50d0fc9-729e-4821-a271-31dbf9303512

Aduro Logo


[ Back To TMCnet.com's Homepage ]